Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

BACKGROUND: Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission by week 14 after 3 induction dos...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Inflamm Bowel Dis
Autores principales: Feagan, Brian G, Schreiber, Stefan, Wolf, Douglas C, Axler, Jeffrey L, Kaviya, Arpeat, James, Alexandra, Curtis, Rebecca I, Geransar, Parnia, Stallmach, Andreas, Ehehalt, Robert, Bokemeyer, Bernd, Khalid, Javaria Mona, O’Byrne, Sharon
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Original Clinical Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499937/
https://ncbi.nlm.nih.gov/pubmed/30365009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy323
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares